{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:12:00Z","timestamp":1789506720378,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020362","name":"INTERREG IVB NWE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001866","name":"National Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001866","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.drudis.2026.104742","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:15:51Z","timestamp":1784330151000},"page":"104742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brain organoids in Parkinson\u2019s disease drug development: Human-specific models for translational discovery"],"prefix":"10.1016","volume":"31","author":[{"given":"Alise","family":"Zagare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Jarazo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4496-0559","authenticated-orcid":false,"given":"Jens","family":"Schwamborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104742_b0005","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-080952","article-title":"Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021","volume":"388","author":"Su","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.drudis.2026.104742_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.tice.2026.103401","article-title":"Advances in cellular and structural engineering of brain organoids for disease modeling: a comprehensive review","volume":"101","author":"Kim","year":"2026","journal-title":"Tissue Cell"},{"key":"10.1016\/j.drudis.2026.104742_b0015","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70395","article-title":"Brain organoids as emerging platforms for modeling neurodegenerative diseases: progress, challenges, and future directions","volume":"170","author":"Kaya","year":"2026","journal-title":"J Neurochem"},{"key":"10.1016\/j.drudis.2026.104742_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2026.1764964","article-title":"Brain organoids as precision models for neurodegenerative diseases: from disease modeling to drug discovery","volume":"20","author":"Zheng","year":"2026","journal-title":"Front Neurosci"},{"key":"10.1016\/j.drudis.2026.104742_bib366","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41531-024-00799-8","article-title":"Human midbrain organoids: a powerful tool for advanced Parkinson\u2019s disease modeling and therapy exploration","volume":"10","author":"Cui","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.drudis.2026.104742_bib367","first-page":"2","article-title":"Midbrain organoids\u2014development and applications in Parkinson\u2019s disease","author":"Toh","year":"2023","journal-title":"Oxf Open Neurosci"},{"key":"10.1016\/j.drudis.2026.104742_b0025","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s13311-013-0234-1","article-title":"Animal models of Parkinson\u2019s disease: a gateway to therapeutics?","volume":"11","author":"Le","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drudis.2026.104742_b0030","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/02611929231157756","article-title":"Poor translatability of biomedical research using animals \u2013 a narrative review","volume":"51","author":"Marshall","year":"2023","journal-title":"Altern Lab Anim"},{"key":"10.1016\/j.drudis.2026.104742_b0035","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3233\/JPD-202184","article-title":"Parkinson\u2019s disease drug development since 1999: a story of repurposing and relative success","volume":"11","author":"Boucherie","year":"2021","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.drudis.2026.104742_b0040","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-240272","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.drudis.2026.104742_b0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41531-023-00589-8","article-title":"Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson\u2019s disease \u2013 Network meta-analysis","volume":"9","author":"Sako","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.drudis.2026.104742_b0050","doi-asserted-by":"crossref","first-page":"25091","DOI":"10.1038\/s41598-025-10912-3","article-title":"Structural differences between human and mouse neurons and their implementation in generative AIs","volume":"15","author":"Saiga","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2026.104742_b0055","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.cell.2016.09.027","article-title":"Molecular diversity of midbrain development in mouse, human, and stem cells","volume":"167","author":"La Manno","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2026.104742_b0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00335-011-9330-x","article-title":"Parkinson\u2019s disease mouse models in translational research","volume":"22","author":"Antony","year":"2011","journal-title":"Mamm Genome"},{"key":"10.1016\/j.drudis.2026.104742_b0065","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejphar.2015.03.021","article-title":"Mouse models rarely mimic the transcriptome of human neurodegenerative diseases: a systematic bioinformatics-based critique of preclinical models","volume":"759","author":"Burns","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.drudis.2026.104742_b0070","article-title":"Limitations of animal models of Parkinson\u2019s disease","volume":"2011","author":"Potashkin","year":"2010","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.drudis.2026.104742_b0075","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/iub.2595","article-title":"Central nervous system organoids for modeling neurodegenerative diseases","volume":"74","author":"Hou","year":"2022","journal-title":"IUBMB Life"},{"key":"10.1016\/j.drudis.2026.104742_b0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s12035-025-05293-7","article-title":"Brain organoids in neurodegenerative disease modeling: advances, applications and future perspectives","volume":"63","author":"Wang","year":"2026","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.drudis.2026.104742_b0085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ajhg.2021.12.009","article-title":"Midbrain organoids mimic early embryonic neurodevelopment and recapitulate LRRK2-p.Gly2019Ser-associated gene expression","volume":"109","author":"Zagare","year":"2022","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.drudis.2026.104742_b0090","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41531-019-0078-4","article-title":"Modeling Parkinson\u2019s disease in midbrain-like organoids","volume":"5","author":"Smits","year":"2019","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.drudis.2026.104742_b0095","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41531-023-00616-8","article-title":"Impaired neuron differentiation in GBA-associated Parkinson\u2019s disease is linked to cell cycle defects in organoids","volume":"9","author":"Rosety","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.drudis.2026.104742_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2024.103919","article-title":"Alpha-synuclein pathology is associated with astrocyte senescence in a midbrain organoid model of familial Parkinson\u2019s disease","volume":"128","author":"Muwanigwa","year":"2024","journal-title":"Mol Cell Neurosci"},{"key":"10.1016\/j.drudis.2026.104742_b0105","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/brain\/awae365","article-title":"Lewy pathology formation in patient-derived GBA1 Parkinson\u2019s disease midbrain organoids","volume":"148","author":"Frattini","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2026.104742_b0110","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab223","article-title":"Midbrain organoids with an SNCA gene triplication model key features of synucleinopathy","volume":"3","author":"Mohamed","year":"2021","journal-title":"Brain Commun"},{"key":"10.1016\/j.drudis.2026.104742_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113541","article-title":"Reproducibility of PD patient-specific midbrain organoid data for in vitro disease modeling","volume":"28","author":"Zuccoli","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.drudis.2026.104742_b0120","doi-asserted-by":"crossref","first-page":"12523","DOI":"10.3390\/ijms252312523","article-title":"Human-induced pluripotent stem cell-derived neural organoids as a novel in vitro platform for developmental neurotoxicity assessment","volume":"25","author":"Hongen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104742_b0125","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4103\/NRR.NRR-D-23-00928","article-title":"Establishment of human cerebral organoid systems to model early neural development and assess the central neurotoxicity of environmental toxins","volume":"20","author":"Hu","year":"2025","journal-title":"Neural Regen Res"},{"key":"10.1016\/j.drudis.2026.104742_b0130","doi-asserted-by":"crossref","first-page":"12516","DOI":"10.1073\/pnas.1516645112","article-title":"Human pluripotent stem cell-derived neural constructs for predicting neural toxicity","volume":"112","author":"Schwartz","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2026.104742_b0135","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.stem.2023.05.015","article-title":"Advanced human iPSC-based preclinical model for Parkinson\u2019s disease with optogenetic alpha-synuclein aggregation","volume":"30","author":"Kim","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drudis.2026.104742_b0140","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1186\/s12967-024-05551-7","article-title":"Tilorone mitigates the propagation of \u03b1-synucleinopathy in a midbrain-like organoid model","volume":"22","author":"Zhang","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2026.104742_b0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau3960","article-title":"A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson\u2019s disease","volume":"12","author":"Boussaad","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2026.104742_b0150","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/mds.28810","article-title":"Parkinson\u2019s disease phenotypes in patient neuronal cultures and brain organoids improved by 2\u2010hydroxypropyl\u2010\u03b2\u2010cyclodextrin treatment","volume":"37","author":"Jarazo","year":"2022","journal-title":"Mov Disord"},{"key":"10.1016\/j.drudis.2026.104742_b0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/mds.30039","article-title":"Insulin resistance is a modifying factor for Parkinson\u2019s disease","volume":"40","author":"Zagare","year":"2025","journal-title":"Mov Disord"},{"key":"10.1016\/j.drudis.2026.104742_b0160","unstructured":"FDA Modernization Act 2.0, S.5002, 117th Congress (2022). https:\/\/www.congress.gov\/bill\/117th-congress\/senate-bill\/5002. Accessed May 29, 2026."},{"key":"10.1016\/j.drudis.2026.104742_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.tibtech.2025.12.011","article-title":"The FDA\u2019s plan to phase out animal testing","author":"Gerke","year":"2026","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.drudis.2026.104742_b0170","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1007\/s00204-022-03365-4","article-title":"A framework for establishing scientific confidence in new approach methodologies","volume":"96","author":"van der Zalm","year":"2022","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.drudis.2026.104742_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2026.104608","article-title":"Organoids in drug development: from predictive models to regulatory integration","volume":"31","author":"Song","year":"2026","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2026.104742_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32965","article-title":"Current trends and research topics regarding organoids: a bibliometric analysis of global research from 2000 to 2023","volume":"10","author":"Wan","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.drudis.2026.104742_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1526306","article-title":"Human-based complex in vitro models: their promise and potential for rare disease therapeutics","volume":"13","author":"Parvatam","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.drudis.2026.104742_b0190","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104742_b0195","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202101176","article-title":"Patient\u2010derived organoids can guide personalized\u2010therapies for patients with advanced breast cancer","volume":"8","author":"Chen","year":"2021","journal-title":"Adv Sci"},{"key":"10.1016\/j.drudis.2026.104742_b0200","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/s41467-020-15155-6","article-title":"An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity","volume":"11","author":"Calandrini","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104742_b0205","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.gendis.2023.02.052","article-title":"Cancer organoids: a platform in basic and translational research","volume":"11","author":"Ma","year":"2024","journal-title":"Genes Dis"},{"key":"10.1016\/j.drudis.2026.104742_b0210","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/toxics12050371","article-title":"Validating well-functioning hepatic organoids for toxicity evaluation","volume":"12","author":"Choi","year":"2024","journal-title":"Toxics"},{"key":"10.1016\/j.drudis.2026.104742_b0215","doi-asserted-by":"crossref","DOI":"10.1126\/science.1247125","article-title":"Organogenesis in a dish: Modeling development and disease using organoid technologies","volume":"345","author":"Lancaster","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.drudis.2026.104742_b0220","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.stemcr.2017.03.010","article-title":"Derivation of human midbrain-specific organoids from neuroepithelial stem cells","volume":"8","author":"Monzel","year":"2017","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.drudis.2026.104742_b0225","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1021\/acschemneuro.3c00246","article-title":"Quantitative and qualitative analysis of neurotransmitter and neurosteroid production in cerebral organoids during differentiation","volume":"14","author":"Park","year":"2023","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.drudis.2026.104742_b0230","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1016\/j.celrep.2016.12.001","article-title":"Cerebral organoids recapitulate epigenomic signatures of the human fetal brain","volume":"17","author":"Luo","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2026.104742_b0235","doi-asserted-by":"crossref","first-page":"7302","DOI":"10.1038\/s41467-021-27464-5","article-title":"Single-cell transcriptomics captures features of human midbrain development and dopamine neuron diversity in brain organoids","volume":"12","author":"Fiorenzano","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104742_b0240","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.stem.2016.07.005","article-title":"Midbrain-like organoids from human pluripotent stem cells contain functional dopaminergic and neuromelanin-producing neurons","volume":"19","author":"Jo","year":"2016","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.drudis.2026.104742_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/6a917a2e-df4a-4ad9-99bb-6aa7218b833e","article-title":"Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling","volume":"8","author":"Reinhardt","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2026.104742_b0250","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12974-025-03577-2","article-title":"The Parkinson\u2019s disease-associated LRRK2-G2019S variant restricts serine metabolism, leading to microglial inflammation and dopaminergic neuron degeneration","volume":"22","author":"Kurniawan","year":"2025","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.drudis.2026.104742_b0255","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1093\/brain\/awaf051","article-title":"Parkinson\u2019s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss","volume":"148","author":"Chemla","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.drudis.2026.104742_b0260","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41531-026-01330-x","article-title":"Autophagy dysfunction in iPSCs-derived neurons and midbrain organoids carrying a SNCA triplication","volume":"12","author":"Serra-Almeida","year":"2026","journal-title":"NPJ Parkinsons Dis"},{"key":"10.1016\/j.drudis.2026.104742_b0265","doi-asserted-by":"crossref","unstructured":"Zimmermann A-S et al. Vascularized midbrain assembloids show neuroinflammation and dopaminergic neuron vulnerability in Parkinson\u2019s disease. bioRxiv. Preprint posted online August 7, 2025. https:\/\/doi.org\/10.1101\/2025.08.06.668815.","DOI":"10.1101\/2025.08.06.668815"},{"key":"10.1016\/j.drudis.2026.104742_b0270","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/glia.24167","article-title":"Microglia integration into human midbrain organoids leads to increased neuronal maturation and functionality","volume":"70","author":"Sabate-Soler","year":"2022","journal-title":"Glia"},{"key":"10.1016\/j.drudis.2026.104742_b0275","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1371\/journal.pbio.0020327","article-title":"Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: an ES- derived cell model of primary Parkinsonism","volume":"2","author":"Martinat","year":"2004","journal-title":"PLoS Biol"},{"key":"10.1016\/j.drudis.2026.104742_b0280","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12964-025-02136-9","article-title":"Neuroprotective role and mechanistic insights of DJ-1 dimerization in Parkinson\u2019s disease","volume":"23","author":"Lv","year":"2025","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.drudis.2026.104742_b0285","doi-asserted-by":"crossref","first-page":"10211","DOI":"10.1074\/jbc.M113.506246","article-title":"2-Hydroxypropyl-\u03b2-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy","volume":"289","author":"Song","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2026.104742_b0290","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.3390\/cells12212565","article-title":"Treating Parkinson\u2019s disease with human bone marrow mesenchymal stem cell secretome: a translational investigation using human brain organoids and different routes of in vivo administration","volume":"12","author":"Mendes-Pinheiro","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2026.104742_b0295","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1021\/acssensors.4c00476","article-title":"Drug evaluation of Parkinson\u2019s disease patient-derived midbrain organoids using mesoporous Au nanodot-patterned 3D concave electrode","volume":"9","author":"An","year":"2024","journal-title":"ACS Sens"},{"key":"10.1016\/j.drudis.2026.104742_b0300","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1042\/bj3150369","article-title":"Tilorone-induced lysosomal lesions: the bisbasic character of the drug is essential for its high potency to cause storage of sulphated glycosaminoglycans","volume":"315","author":"Fischer","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.drudis.2026.104742_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2020.101870","article-title":"Reproducible generation of human midbrain organoids for in vitro modeling of Parkinson\u2019s disease","volume":"46","author":"Nickels","year":"2020","journal-title":"Stem Cell Res"},{"key":"10.1016\/j.drudis.2026.104742_b0310","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/stem.3163","article-title":"Generation of homogeneous midbrain organoids with in vivo-like cellular composition facilitates neurotoxin-based Parkinson\u2019s disease modeling","volume":"38","author":"Kwak","year":"2020","journal-title":"Stem Cells"},{"key":"10.1016\/j.drudis.2026.104742_b0315","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/3320211","article-title":"Production of highly uniform midbrain organoids from human pluripotent stem cells","volume":"2023","author":"Yao","year":"2023","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.drudis.2026.104742_b0320","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1039\/D0AN02206C","article-title":"Monitoring the neurotransmitter release of human midbrain organoids using a redox cycling microsensor as a novel tool for personalized Parkinson\u2019s disease modelling and drug screening","volume":"146","author":"Zanetti","year":"2021","journal-title":"Analyst"},{"key":"10.1016\/j.drudis.2026.104742_b0325","doi-asserted-by":"crossref","first-page":"6217","DOI":"10.1039\/D2SC00809B","article-title":"Dysfunction of vesicular storage in young-onset Parkinson\u2019s patient-derived dopaminergic neurons and organoids revealed by single cell electrochemical cytometry","volume":"13","author":"Zhu","year":"2022","journal-title":"Chem Sci"},{"key":"10.1016\/j.drudis.2026.104742_b0330","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/s13287-025-04660-4","article-title":"Three-dimensional midbrain organoids: a next-generation tool for Parkinson\u2019s disease modelling and drug discovery","volume":"16","author":"Elvira","year":"2025","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.drudis.2026.104742_b0335","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1038\/s44318-025-00494-1","article-title":"Advances, challenges, and opportunities of human midbrain organoids for modelling of the dopaminergic system","volume":"44","author":"Fiorenzano","year":"2025","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2026.104742_b0340","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/s42003-024-07273-4","article-title":"Modeling early phenotypes of Parkinson\u2019s disease by age-induced midbrain-striatum assembloids","volume":"7","author":"Barmpa","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.drudis.2026.104742_b0345","article-title":"\u03b1-Synuclein pathology spreads in a midbrain-hindbrain assembloid model","volume":"12","author":"Gomez-Giro","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.drudis.2026.104742_b0350","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41586-024-07578-8","article-title":"Brain chimeroids reveal individual susceptibility to neurotoxic triggers","volume":"631","author":"Ant\u00f3n-Bola\u00f1os","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104742_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00436","article-title":"Bioreactor-produced iPSCs-derived dopaminergic neuron-containing neural microtissues innervate and normalize rotational bias in a dose-dependent manner in a Parkinson rat model","volume":"21","author":"Prudon","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.drudis.2026.104742_b0360","doi-asserted-by":"crossref","DOI":"10.1038\/s41684-026-01731-8","article-title":"What\u2019s in a NAM?","author":"Ahluwalia","year":"2026","journal-title":"Lab Anim"},{"key":"10.1016\/j.drudis.2026.104742_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113831","article-title":"Variability vs. phenotype: multimodal analysis of Dravet syndrome brain organoids powered by deep learning","volume":"28","author":"Turpin-Moreno","year":"2025","journal-title":"iScience"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626001479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:45:40Z","timestamp":1789505140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626001479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1359644626001479"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104742","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain organoids in Parkinson\u2019s disease drug development: Human-specific models for translational discovery","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104742"}}